Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections

Yanina Dubrovskaya, Ting Yi Chen, Marco R. Scipione, Diana Esaian, Michael S. Phillips, John Papadopoulos, Sapna A. Mehta

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Polymyxins are reserved for salvage therapy of infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). Though synergy has been demonstrated for the combination of polymyxins with carbapenems or tigecycline, in vitro synergy tests are nonstandardized, and the clinical effect of synergy remains unclear. This study describes outcomes for patients with CRKP infections who were treated with polymyxin B monotherapy. We retrospectively reviewed the medical records of patients with CRKP infections who received polymyxin B monotherapy from 2007 to 2011. Clinical, microbiology, and antimicrobial treatment data were collected. Risk factors for treatment failure were identified by logistic regression. Forty patients were included in the analysis. Twenty-nine of 40 (73%) patients achieved clinical cure as defined by clinician-documented improvement in signs and symptoms of infections, and 17/32 (53%) patients with follow-up culture data achieved microbiological cure. Endof- treatment mortality was 10%, and 30-day mortality was 28%. In a multivariate analysis, baseline renal insufficiency was associated with a 6.0-fold increase in clinical failure after adjusting for septic shock (odds ratio [OR]=6.0; 95% confidence interval [CI]=1.22 to 29.59). Breakthrough infections with organisms intrinsically resistant to polymyxins occurred in 3 patients during the treatment. Eighteen of 40 (45%) patients developed a new CRKP infection a median of 23 days after initial polymyxin B treatment, and 3 of these 18 infections were polymyxin resistant. The clinical cure rate achieved in this retrospective study was 73% of patients with CRKP infections treated with polymyxin B monotherapy. Baseline renal insufficiency was a risk factor for treatment failure after adjusting for septic shock. Breakthrough infections with organisms intrinsically resistant to polymyxin B and development of resistance to polymyxin B in subsequent CRKP isolates are of concern.

Original languageEnglish (US)
Pages (from-to)5394-5397
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume57
Issue number11
DOIs
StatePublished - Nov 2013

Fingerprint

Klebsiella Infections
Polymyxin B
Carbapenems
Klebsiella pneumoniae
Treatment Failure
Polymyxins
Infection
Septic Shock
Renal Insufficiency
Salvage Therapy
Mortality
Therapeutics
Microbiology
Signs and Symptoms
Medical Records
Multivariate Analysis
Retrospective Studies
Logistic Models
Odds Ratio
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Dubrovskaya, Y., Chen, T. Y., Scipione, M. R., Esaian, D., Phillips, M. S., Papadopoulos, J., & Mehta, S. A. (2013). Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrobial Agents and Chemotherapy, 57(11), 5394-5397. https://doi.org/10.1128/AAC.00510-13

Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. / Dubrovskaya, Yanina; Chen, Ting Yi; Scipione, Marco R.; Esaian, Diana; Phillips, Michael S.; Papadopoulos, John; Mehta, Sapna A.

In: Antimicrobial Agents and Chemotherapy, Vol. 57, No. 11, 11.2013, p. 5394-5397.

Research output: Contribution to journalArticle

Dubrovskaya, Y, Chen, TY, Scipione, MR, Esaian, D, Phillips, MS, Papadopoulos, J & Mehta, SA 2013, 'Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections', Antimicrobial Agents and Chemotherapy, vol. 57, no. 11, pp. 5394-5397. https://doi.org/10.1128/AAC.00510-13
Dubrovskaya, Yanina ; Chen, Ting Yi ; Scipione, Marco R. ; Esaian, Diana ; Phillips, Michael S. ; Papadopoulos, John ; Mehta, Sapna A. / Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. In: Antimicrobial Agents and Chemotherapy. 2013 ; Vol. 57, No. 11. pp. 5394-5397.
@article{4acaf166fbd5410e8599a20729e7d9e1,
title = "Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections",
abstract = "Polymyxins are reserved for salvage therapy of infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). Though synergy has been demonstrated for the combination of polymyxins with carbapenems or tigecycline, in vitro synergy tests are nonstandardized, and the clinical effect of synergy remains unclear. This study describes outcomes for patients with CRKP infections who were treated with polymyxin B monotherapy. We retrospectively reviewed the medical records of patients with CRKP infections who received polymyxin B monotherapy from 2007 to 2011. Clinical, microbiology, and antimicrobial treatment data were collected. Risk factors for treatment failure were identified by logistic regression. Forty patients were included in the analysis. Twenty-nine of 40 (73{\%}) patients achieved clinical cure as defined by clinician-documented improvement in signs and symptoms of infections, and 17/32 (53{\%}) patients with follow-up culture data achieved microbiological cure. Endof- treatment mortality was 10{\%}, and 30-day mortality was 28{\%}. In a multivariate analysis, baseline renal insufficiency was associated with a 6.0-fold increase in clinical failure after adjusting for septic shock (odds ratio [OR]=6.0; 95{\%} confidence interval [CI]=1.22 to 29.59). Breakthrough infections with organisms intrinsically resistant to polymyxins occurred in 3 patients during the treatment. Eighteen of 40 (45{\%}) patients developed a new CRKP infection a median of 23 days after initial polymyxin B treatment, and 3 of these 18 infections were polymyxin resistant. The clinical cure rate achieved in this retrospective study was 73{\%} of patients with CRKP infections treated with polymyxin B monotherapy. Baseline renal insufficiency was a risk factor for treatment failure after adjusting for septic shock. Breakthrough infections with organisms intrinsically resistant to polymyxin B and development of resistance to polymyxin B in subsequent CRKP isolates are of concern.",
author = "Yanina Dubrovskaya and Chen, {Ting Yi} and Scipione, {Marco R.} and Diana Esaian and Phillips, {Michael S.} and John Papadopoulos and Mehta, {Sapna A.}",
year = "2013",
month = "11",
doi = "10.1128/AAC.00510-13",
language = "English (US)",
volume = "57",
pages = "5394--5397",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections

AU - Dubrovskaya, Yanina

AU - Chen, Ting Yi

AU - Scipione, Marco R.

AU - Esaian, Diana

AU - Phillips, Michael S.

AU - Papadopoulos, John

AU - Mehta, Sapna A.

PY - 2013/11

Y1 - 2013/11

N2 - Polymyxins are reserved for salvage therapy of infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). Though synergy has been demonstrated for the combination of polymyxins with carbapenems or tigecycline, in vitro synergy tests are nonstandardized, and the clinical effect of synergy remains unclear. This study describes outcomes for patients with CRKP infections who were treated with polymyxin B monotherapy. We retrospectively reviewed the medical records of patients with CRKP infections who received polymyxin B monotherapy from 2007 to 2011. Clinical, microbiology, and antimicrobial treatment data were collected. Risk factors for treatment failure were identified by logistic regression. Forty patients were included in the analysis. Twenty-nine of 40 (73%) patients achieved clinical cure as defined by clinician-documented improvement in signs and symptoms of infections, and 17/32 (53%) patients with follow-up culture data achieved microbiological cure. Endof- treatment mortality was 10%, and 30-day mortality was 28%. In a multivariate analysis, baseline renal insufficiency was associated with a 6.0-fold increase in clinical failure after adjusting for septic shock (odds ratio [OR]=6.0; 95% confidence interval [CI]=1.22 to 29.59). Breakthrough infections with organisms intrinsically resistant to polymyxins occurred in 3 patients during the treatment. Eighteen of 40 (45%) patients developed a new CRKP infection a median of 23 days after initial polymyxin B treatment, and 3 of these 18 infections were polymyxin resistant. The clinical cure rate achieved in this retrospective study was 73% of patients with CRKP infections treated with polymyxin B monotherapy. Baseline renal insufficiency was a risk factor for treatment failure after adjusting for septic shock. Breakthrough infections with organisms intrinsically resistant to polymyxin B and development of resistance to polymyxin B in subsequent CRKP isolates are of concern.

AB - Polymyxins are reserved for salvage therapy of infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). Though synergy has been demonstrated for the combination of polymyxins with carbapenems or tigecycline, in vitro synergy tests are nonstandardized, and the clinical effect of synergy remains unclear. This study describes outcomes for patients with CRKP infections who were treated with polymyxin B monotherapy. We retrospectively reviewed the medical records of patients with CRKP infections who received polymyxin B monotherapy from 2007 to 2011. Clinical, microbiology, and antimicrobial treatment data were collected. Risk factors for treatment failure were identified by logistic regression. Forty patients were included in the analysis. Twenty-nine of 40 (73%) patients achieved clinical cure as defined by clinician-documented improvement in signs and symptoms of infections, and 17/32 (53%) patients with follow-up culture data achieved microbiological cure. Endof- treatment mortality was 10%, and 30-day mortality was 28%. In a multivariate analysis, baseline renal insufficiency was associated with a 6.0-fold increase in clinical failure after adjusting for septic shock (odds ratio [OR]=6.0; 95% confidence interval [CI]=1.22 to 29.59). Breakthrough infections with organisms intrinsically resistant to polymyxins occurred in 3 patients during the treatment. Eighteen of 40 (45%) patients developed a new CRKP infection a median of 23 days after initial polymyxin B treatment, and 3 of these 18 infections were polymyxin resistant. The clinical cure rate achieved in this retrospective study was 73% of patients with CRKP infections treated with polymyxin B monotherapy. Baseline renal insufficiency was a risk factor for treatment failure after adjusting for septic shock. Breakthrough infections with organisms intrinsically resistant to polymyxin B and development of resistance to polymyxin B in subsequent CRKP isolates are of concern.

UR - http://www.scopus.com/inward/record.url?scp=84885903528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885903528&partnerID=8YFLogxK

U2 - 10.1128/AAC.00510-13

DO - 10.1128/AAC.00510-13

M3 - Article

VL - 57

SP - 5394

EP - 5397

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -